復星醫藥(600196.SH):“復宏漢霖生物醫藥產業化基地(二)”一期項目增加第三階段投資不超8.18億元
格隆匯11月9日丨復星醫藥(600196.SH)公佈,2021年11月9日,經公司第八屆第五十六次董事會審議通過,同意此次建設項目增加第三階段投資不超過人民幣8.18億元(全部為固定資產投資)。該事項無需提請公司股東大會批准。
項目內容:“復宏漢霖生物醫藥產業化基地(二)”一期項目。項目所涉主要產品: 該建設項目所涉產品主要包括已上市產品利妥昔單抗注射液(漢利康)、注射用曲妥珠單抗(漢曲優)、阿達木單抗注射液(漢達遠)及處於上市註冊申請階段的斯魯利單抗注射液,未來可能根據已上市產品的市場需求、擬上市/在研產品的商業化進程等實際情況進行增加或調整。
此次建設項目總投資金額不超過人民幣25.38億元(其中:固定資產總投資不超過人民幣24.08億元、鋪底流動資金不超過人民幣1.3億元)。其中,第一階段投資不超過人民幣10億元、建設週期為3年;第二階段投資不超過人民幣7.2億元、建設週期為2年;第三階段投資不超過人民幣8.18億元、建設週期為3年。
此次建設項目追加第三階段投資,主要為滿足復宏漢霖及/或其控股子公司已上市產品的市場需求和配合擬上市產品的商業化進程、提高產能保障。 該建設項目建設完成後將成為集團單克隆抗體生物藥研發、中試及生產基地,有利於進一步增強集團在生物藥領域的研發實力,並滿足生物類似藥、生物創新藥產品的商業化生產需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.